

Objective:

To ensure that Tuality Health Alliance female members ages 19-26 who meet certain Center for Disease Control guidelines are provided the opportunity to receive the Gardasil vaccination to protect them from Human Papilloma Virus (HPV).

Policy:

- I. The vaccine is available to children up to the age of 19 through the Vaccines for Children program.
 - A. Female children may be immunized beginning at 11 years of age (prior to sexual activity) to instill full protection. For high risk female patients, this may be given as early as 9 years of age.
 - B. Recommended dose regimen of three doses is considered complete.
- II. The vaccine will be made available to THA Oregon Health Plan women ages 19-26. Considerations:
 - A. Prevacination assessments (e.g., Pap testing or screening for high-risk HPV DNA, type-specific HPV tests, or HPV antibody) to establish the appropriateness of HPV vaccination are not recommended at any age.
 - B. A history of genital warts or clinically evident genital warts indicates infection with HPV, most often HPV 6 or 11. Vaccination is still recommended for such females because vaccination can provide protection against infection with HPV vaccine types not already acquired. Females should be advised that vaccination will have no therapeutic effect on an existing HPV infection or genital warts
 - C. Lactating women can receive HPV vaccine.
- III. CPT Code for PAP and HPV testing are 87620 – 87622
- IV. Contraindications for therapy are as follows:
 - A. Currently pregnant
 - B. History of immediate sensitivity to yeast or yeast products
 - C. Doesn't meet above criteria

**Tuality Health Alliance
Clinical Practice Guideline: #THAIX-6**

Subject: Gardasil

Page 2 of 2

Reference: Gardasil (Quadrivalent Human Papillomavirus Types 6,11,16,18 Recombinant Vaccine). “An analysis of disease burden, efficacy in North American Women”.

<http://www.cdc.gov/vaccines/vpd-vac/hpv/default.htm>

Morbidity and Mortality Weekly Report (MMWR)” FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and Guidance from the Advisory Committee on Immunization Practices (ACIP)”. May 28, 2010/ 50(20);630-632

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a5.htm?s_cid=mm5920a5_e

http://www.cdc.gov/mmwr/mmwr_wk/wk_cvol.html

Formulated: April 2007

Revised: February 2011

THA Plan Director

THA Medical Director